Polypharmacy in Osteoporosis Treatment
Authors:
- 13 September 2022
- journal article
- research article
- Published by Elsevier in Clinics in Geriatric Medicine
- Vol. 38 (4) , 715-726
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Polypharmacy Correlates With Increased Risk for Hip Fracture in the ElderlyMedicine, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Zoledronic Acid and Clinical Fractures and Mortality after Hip FractureNew England Journal of Medicine, 2007
- Loss of treatment benefit due to low compliance with bisphosphonate therapyOsteoporosis International, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Polypharmacy in the elderly: A literature reviewJournal of the American Academy of Nurse Practitioners, 2005
- Potential Pitfalls of Disease-Specific Guidelines for Patients with Multiple ConditionsNew England Journal of Medicine, 2004
- Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2004
- Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2001
- Effect of Risedronate on the Risk of Hip Fracture in Elderly WomenNew England Journal of Medicine, 2001